open access

Vol 14, No 1 (2011)
Original articles
Published online: 2011-07-12
Submitted: 2012-01-23
Get Citation

Lithium carbonate pre-treatment in 131-I therapy of hyperthyroidism

Maria Teresa Płazińska, Leszek Królicki, Marianna Bąk
Nucl. Med. Rev 2011;14(1):3-8.

open access

Vol 14, No 1 (2011)
Original articles
Published online: 2011-07-12
Submitted: 2012-01-23

Abstract

BACKGROUND: The aim of the present work was to investigate the influence of lithium carbonate on the kinetics of radioiodine in the thyroid gland, and the long-lasting effect of radioiodine therapy pre-treated with lithium carbonate in patients with different types of hyperthyreosis and low baseline 24-h thyroidal radioactive iodine uptake (RAIU).
MATERIAL AND METHODS: The examinations were performed in two groups of patients: in a control group with RAIU > 30% and in patients with RAIU < 30%. All groups were comparable with regard to age, sex, duration and type of disease (Graves’ disease, autonomous node, multinodular goitre). The control group was treated (without lithium) according to described protocol. The second group was pre-treated with lithium carbonate in a dose of 1.0 g/day for 6 days before radioiodine and 3 days thereafter.
RESULTS: A significant increase in iodide uptake in the thyroid gland was observed during intake of lithium carbonate in 106 out of 128 patients. A decrease of T3, FT3, T4, and FT4 levels and no significant changes in concentration of TSH were observed as an effect of lithium carbonate treatment. Three years of follow-up show that the results of radioiodine therapy with short lasting lithium carbonate intake are better in the first year and are similar in the second and third years in comparison to the control group.
CONCLUSIONS: Lithium pre-treatment in hyperthyroid patients with low baseline uptake of radioiodine can increase iodine retention in the thyroid gland independently of the primary disease and permits the use of lower doses of radiation in the therapy.
Nuclear Med Rev 2011; 14, 1: 3–8

Abstract

BACKGROUND: The aim of the present work was to investigate the influence of lithium carbonate on the kinetics of radioiodine in the thyroid gland, and the long-lasting effect of radioiodine therapy pre-treated with lithium carbonate in patients with different types of hyperthyreosis and low baseline 24-h thyroidal radioactive iodine uptake (RAIU).
MATERIAL AND METHODS: The examinations were performed in two groups of patients: in a control group with RAIU > 30% and in patients with RAIU < 30%. All groups were comparable with regard to age, sex, duration and type of disease (Graves’ disease, autonomous node, multinodular goitre). The control group was treated (without lithium) according to described protocol. The second group was pre-treated with lithium carbonate in a dose of 1.0 g/day for 6 days before radioiodine and 3 days thereafter.
RESULTS: A significant increase in iodide uptake in the thyroid gland was observed during intake of lithium carbonate in 106 out of 128 patients. A decrease of T3, FT3, T4, and FT4 levels and no significant changes in concentration of TSH were observed as an effect of lithium carbonate treatment. Three years of follow-up show that the results of radioiodine therapy with short lasting lithium carbonate intake are better in the first year and are similar in the second and third years in comparison to the control group.
CONCLUSIONS: Lithium pre-treatment in hyperthyroid patients with low baseline uptake of radioiodine can increase iodine retention in the thyroid gland independently of the primary disease and permits the use of lower doses of radiation in the therapy.
Nuclear Med Rev 2011; 14, 1: 3–8
Get Citation

Keywords

lithium carbonate; 131-Iodine; hyperthyroidism; Graves’ disease; multinodular goitre; autonomous tumour

About this article
Title

Lithium carbonate pre-treatment in 131-I therapy of hyperthyroidism

Journal

Nuclear Medicine Review

Issue

Vol 14, No 1 (2011)

Pages

3-8

Published online

2011-07-12

Bibliographic record

Nucl. Med. Rev 2011;14(1):3-8.

Keywords

lithium carbonate
131-Iodine
hyperthyroidism
Graves’ disease
multinodular goitre
autonomous tumour

Authors

Maria Teresa Płazińska
Leszek Królicki
Marianna Bąk

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl